PMID- 29979410
OWN - NLM
STAT- MEDLINE
DCOM- 20180717
LR  - 20210109
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 27
DP  - 2018 Jul
TI  - Clinical efficacy and safety of nuanxin capsule for chronic heart failure: A 
      systematic review and meta-analysis.
PG  - e11339
LID - 10.1097/MD.0000000000011339 [doi]
LID - e11339
AB  - BACKGROUND: Chronic heart failure (CHF), the final phase of various heart 
      diseases, is a serious public health problem resulting in high hospitalization 
      rates, mortality, and increasing health care costs. Nuanxin capsule (NXC), a 
      Chinese herbal formula, has been widely used in the treatment of CHF. However, 
      the safety and efficacy of NXC used in patients with CHF has been uncertain and 
      there has been no standard clinical trial published to confirm this. Thus, we 
      conduct a study to evaluate the safety and efficacy of NXC for CHF. METHODS: The 
      reference lists of randomized controlled trials and 8 electronic databases will 
      be independently and systematically searched by 2 review authors in May 2018. 
      Four English databases (EMBASE, PubMed, Cumulative Index to Nursing and Allied 
      Health Literature [CINAHL], and Cochrane Central Register of Controlled Trials 
      [CENTRAL]) and 4 Chinese databases (Chinese Biomedical Literature Database [CBM], 
      Chinese National Knowledge Infrastructure [CNKI], Wanfang Database, and VIP 
      Database) will be included. The primary outcomes will be assessed according to 
      the function classification of New York Heart Association (NYHA). Data synthesis 
      will be precisely computed using the RevManV5.3 software when a data-analysis is 
      allowed. Methodological quality will be assessed according to Cochrane Handbook. 
      RESULTS: This study will provide a high-quality synthesis of current evidence of 
      NXC for CHF from different aspects including the mortality, the function 
      classification of NYHA. CONCLUSION: The conclusion of this systematic review will 
      provide evidence to prove whether NXC is an effective therapeutic intervention 
      for patient with CHF.PROSPERO registration number: PROSPERO CRD42018090003.
FAU - Li, Ziqing
AU  - Li Z
AD  - The Second Clinical School of Guangzhou University of Chinese Medicine Guangdong 
      Provincial Hospital of Chinese Medicine, The Second Clinical School of Guangzhou 
      University of Chinese Medicine, Guangzhou, China.
FAU - Zhang, Yu
AU  - Zhang Y
FAU - Yuan, Tie
AU  - Yuan T
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
SB  - IM
MH  - Chronic Disease
MH  - Drugs, Chinese Herbal/adverse effects/*therapeutic use
MH  - Exercise Test/drug effects
MH  - Heart Failure/*drug therapy
MH  - Humans
MH  - Quality of Life
MH  - Stroke Volume/drug effects
MH  - Treatment Outcome
PMC - PMC6076094
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2018/07/07 06:00
MHDA- 2018/07/18 06:00
PMCR- 2018/07/06
CRDT- 2018/07/07 06:00
PHST- 2018/07/07 06:00 [entrez]
PHST- 2018/07/07 06:00 [pubmed]
PHST- 2018/07/18 06:00 [medline]
PHST- 2018/07/06 00:00 [pmc-release]
AID - 00005792-201807060-00037 [pii]
AID - MD-D-18-04015 [pii]
AID - 10.1097/MD.0000000000011339 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2018 Jul;97(27):e11339. doi: 10.1097/MD.0000000000011339.